Last updated: February 20, 2026
This radiopharmaceutical, Ga-68 EDOTREOTIDE, is used primarily in positron emission tomography (PET) imaging for neuroendocrine tumors. Its suppliers are limited due to the specialized nature of the compound, the radioactive isotope, and the production standards.
Key Suppliers and Manufacturers
| Supplier/Manufacturer |
Location |
Capabilities |
Notes |
| IRE ELiT (part of Advanced Accelerator Applications, a Novartis company) |
France |
Supplies Ga-68 generators and radiopharmaceuticals, including DOTATATE, which can be labeled with Ga-68 |
Leading provider of Ga-68 generators, supplies raw material for EDOTREOTIDE production |
| Curium (a Navitas Semiconductor division) |
Switzerland |
Produces Ga-68 generators and radiopharmaceuticals |
Supplies Ga-68 generators primarily for medical imaging |
| Eckert & Ziegler |
Germany |
Manufacturer of Ga-68 generators and radiopharmaceutical components |
Supplies Ga-68 generators, potential vendor of precursor materials |
| Nordion (Canada) |
Canada |
Provides cyclotron products, including isotopes for radiopharmaceuticals |
Supplies some of the raw isotopes used in production processes |
Production and Supply Chain Dynamics
Ga-68 Generator Suppliers
Ga-68 is obtained from germanium-68/gallium-68 generators. Their regulatory approval varies by region; the main approved vendors are:
- IRE ELiT (France): Supplies generators with yields of approximately 2.2 to 4.1 GBq (60 to 110 mCi) at calibration.
- Curium (Switzerland): Offers generators with similar activity yields.
Raw Material Providers
The production of Ga-68 involves germanium-68, produced via cyclotron irradiation of gallium or enriched targets. Suppliers of germanium-68 include:
- IzfP (Germany)
- American Isotopes (USA)
Pharmaceutical Manufacturers
The actual production of EDOTREOTIDE is performed by licensed pharmaceutical manufacturers, which purchase Ga-68 generators or raw Ga-68 isotopes. Some key licensed producers include:
- Cardinal Health
- Jubilant Radiopharma
Supply Constraints and Market Trends
- The finite availability of germanium-68, which has a half-life of 271 days, limits scaling.
- The global shortage of Ga-68 generators peaked during 2021-2022 due to supply chain disruptions and increased demand for neuroendocrine tumor imaging.
- The shift toward using cyclotron-produced Ga-68 aims to improve supply security.
Regulatory and Certification Factors
- Suppliers must have approvals from agencies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), or respective national authorities.
- Quality assurance measures closely follow pharmacopeial standards set by the European Pharmacopoeia and USP.
Summary of Market Participants
- Primary Ga-68 generator providers: IRE ELiT, Curium
- Raw isotope producers: IzfP, American Isotopes
- Pharmaceutical manufacturers: Cardinal Health, Jubilant Radiopharma
Closing Notes
The supply chain for Ga-68 EDOTREOTIDE is concentrated among few vendors specializing in isotope production and generator manufacturing. Geopolitical issues, production capacity, and regulatory approvals influence supply stability.
Key Takeaways
- Suppliers mainly include IRE ELiT, Curium, Eckert & Ziegler.
- Production relies on germanium-68 generators with limited global capacity.
- Supply disruptions have occurred during recent years due to pandemic-related logistics and isotope shortages.
- Future supply growth depends on expansion of cyclotron-based Ga-68 production.
- Regulatory approvals are critical for market access and supply chain integrity.
FAQs
1. Can Ga-68 EDOTREOTIDE be produced outside of Europe?
Yes, some regions such as North America are developing cyclotron-based Ga-68 production to lessen reliance on European generators.
2. What determines the quality of Ga-68 generators?
Yield, purity, and sterility standards are key; compliance with pharmacopeial standards ensures safety and efficacy.
3. Are there alternatives to Ga-68 EDOTREOTIDE?
Yes, other radiotracers such as F-18 labeled compounds are used for similar imaging, but Ga-68 EDOTREOTIDE remains preferred for neuroendocrine tumors.
4. What are the main logistical challenges in the supply chain?
Generator production capacity, isotope decay (half-life of 68 Ge), and transportation restrictions.
5. How does regional regulation affect supply?
Different approval pathways and certification standards can limit the availability of certain suppliers in jurisdictions outside Europe and North America.
References
- European Medicines Agency. (2021). Guideline on the radiopharmaceuticals used for PET imaging. EMA.
- IRE ELiT. (2022). Ga-68 generator product information. IRE ELiT.
- Curium. (2022). Ga-68 generator specifications and product catalog. Curium.
- U.S. Food and Drug Administration. (2022). Regulatory oversight of radiopharmaceuticals. FDA.
- Nordion. (2022). Cyclotron isotope production overview. Nordion.
